Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
The Massachusetts Democrat is working with a Missouri Republican, and House members from each party, to press the FTC to ...
President Donald Trump's effect on bank capital rules, crypto policy, antitrust scrutiny, and drug pricing are among key 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback